MAP2K7 and carcinoma: Combinations of MEK and mTOR inhibitors have been tested in several carcinomas, including lung cancer (46–48), melanoma (49), colorectal cancer (50), and pancreatic cancer (51), but their combined effect on sarcomas have only been reported for rhabdomysarcoma (31,32).